{"id":544893,"date":"2021-05-26T18:18:02","date_gmt":"2021-05-26T18:18:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=544893"},"modified":"2021-05-26T18:18:02","modified_gmt":"2021-05-26T18:18:02","slug":"lebers-hereditary-optic-neuropathy-market-analysis-market-size-trends-epidemiology-leading-companies-and-therapies-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/lebers-hereditary-optic-neuropathy-market-analysis-market-size-trends-epidemiology-leading-companies-and-therapies-delveinsight_544893.html","title":{"rendered":"Leber\u2019s Hereditary Optic Neuropathy Market Analysis, Market Size, Trends, Epidemiology, Leading Companies And Therapies | DelveInsight"},"content":{"rendered":"
\"Leber’s<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s \u201cLeber\u2019s Hereditary Optic Neuropathy \u2013 Market Insights, Epidemiology, and Market Forecast-2030\u201d report delivers an in-depth understanding of the Leber\u2019s Hereditary Optic Neuropathy , historical and forecasted epidemiology as well as the Leber\u2019s Hereditary Optic Neuropathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<\/div>\n

DelveInsight has launched a new report on “Leber’s Hereditary Optic Neuropathy -Market Insights, Epidemiology, and Market Forecast-2030<\/strong>”.<\/p>\n

DelveInsight’s<\/span> “Leber’s Hereditary Optic Neuropathy  – Market Insights, Epidemiology, and Market Forecast-2030<\/strong><\/a><\/span>” report delivers an in-depth understanding of the Leber’s Hereditary Optic Neuropathy, historical and forecasted epidemiology as well as the  Leber’s Hereditary Optic Neuropathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/span><\/p>\n

Some of the key facts of the Report:<\/span><\/strong><\/p>\n

    \n
  1. \n

    LHON is a rare disease, with an estimated prevalence of between 1 in <\/span>30,000<\/span> and 1 in <\/span>50,000<\/span> reported in Northern Europe. In the northeast of England, the reported prevalence of visual loss due to LHON is <\/span>3.22<\/span> per 100,000 people (Vignal-Clermont et., al 2014)<\/span><\/p>\n<\/li>\n

  2. \n

    According to the National Organization for Rare Disease the prevalence of visual loss from LHON is approximately <\/span>1:50,000<\/span> people. Many carriers never suffer significant visual loss; males are about four to five times more likely than females to lose vision and be affected.<\/span><\/p>\n<\/li>\n

  3. \n

    According to Nationwide epidemiological survey of Leber hereditary optic neuropathy in Japan, approximately <\/span>120 <\/span>cases of newly developed LHON were reported during 2014 in Japan, and 93.2% were males (Ueda et., al 2017)<\/span><\/p>\n<\/li>\n

  4. \n

    Symptom onset typically occurs in the second and third decades of life. LHON carriers rarely lose vision after the age of <\/span>50 <\/span>years, but there have been reports of LHON onset from <\/span>2 <\/span>to <\/span>87<\/span> years of age. (Meyerson et al.)<\/span><\/p>\n<\/li>\n<\/ol>\n

    Key benefits of the report:<\/strong><\/p>\n

    1. Leber’s Hereditary Optic Neuropathy market report covers a descriptive overview and comprehensive insight of the Leber’s Hereditary Optic Neuropathy  epidemiology and Leber’s Hereditary Optic Neuropathy market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/span><\/p>\n

    2. The Leber’s Hereditary Optic Neuropathy market report provides insights on the current and emerging therapies.<\/span><\/p>\n

    3. Leber’s Hereditary Optic Neuropathy market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/span><\/p>\n

    4. The Leber’s Hereditary Optic Neuropathy market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Leber’s Hereditary Optic Neuropathy market.<\/span><\/p>\n

    Request for sample pages<\/span>: https:\/\/www.delveinsight.com\/sample-request\/lebers-hereditary-optic-neuropathy-lhon-market<\/span><\/a><\/span>
    <\/span><\/a><\/strong><\/p>\n

    Leber’s Hereditary Optic Neuropathy: Overview<\/span><\/strong><\/p>\n

    Leber’s hereditary optic neuropathy (LHON) is a distinct type of “inherited optic atrophies” or “hereditary optic neuropathies.” It refers to an optic nerve dysfunction due to point mutations in the mitochondrial DNA and is transmitted in the non-mendelian pattern. The primary cell type lost in LHON is the retinal ganglion cell, which is highly susceptible to disrupted ATP production and oxidative stress. Inheritance of LHON follows mitochondrial genetics, and it has a highly variable clinical phenotype, as other genetic and environmental factors also play a role.<\/span><\/p>\n

    The key players involved in the Leber’s Hereditary Optic Neuropathy market:<\/strong><\/p>\n

      \n
    1. \n

      GenSight<\/span><\/p>\n<\/li>\n

    2. \n

      Stealth Biotherapeutics<\/span><\/p>\n<\/li>\n<\/ol>\n

      The launch of the emerging therapies is expected to significantly impact Leber’s Hereditary Optic Neuropathy treatment<\/a> scenario in the upcoming years:-<\/strong><\/p>\n

      Drug covered<\/span><\/strong><\/p>\n

        \n
      1. \n

        GS010 <\/span><\/p>\n<\/li>\n

      2. \n

        Elamipretide<\/span><\/p>\n<\/li>\n<\/ol>\n

        Request a free sample report @https:\/\/www.delveinsight.com\/sample-request\/lebers-hereditary-optic-neuropathy-lhon-market<\/span><\/a><\/strong><\/p>\n

        Table of Contents<\/span><\/strong><\/p>\n

        1. Report Introduction<\/span><\/p>\n

        2. Executive Summary<\/span><\/p>\n

        3. SWOT analysis<\/span><\/p>\n

        4. Leber’s Hereditary Optic Neuropathy Patient Share (%) Overview at a Glance<\/span><\/p>\n

        5. Leber’s Hereditary Optic Neuropathy Market Overview at a Glance<\/span><\/p>\n

        6. Leber’s Hereditary Optic Neuropathy Disease Background and Overview<\/span><\/p>\n

        7. Leber’s Hereditary Optic Neuropathy Epidemiology and Patient Population<\/span><\/p>\n

        8. Country-Specific Patient Population of Leber’s Hereditary Optic Neuropathy <\/span><\/p>\n

        9. Leber’s Hereditary Optic Neuropathy Current Treatment and Medical Practices<\/span><\/p>\n

        10. Unmet Needs<\/span><\/p>\n

        11. Leber’s Hereditary Optic Neuropathy Emerging Therapies<\/span><\/p>\n

        12. Leber’s Hereditary Optic Neuropathy Market Outlook<\/span><\/p>\n

        13. Country-Wise Leber’s Hereditary Optic Neuropathy Market Analysis (2017–2030)<\/span><\/p>\n

        14. Market Access and Reimbursement of Therapies<\/span><\/p>\n

        15. Market drivers<\/span><\/p>\n

        16. Market barriers<\/span><\/p>\n

        17. Appendix<\/span><\/p>\n

        18. Leber’s Hereditary Optic Neuropathy Report Methodology<\/span><\/p>\n

        19. DelveInsight Capabilities<\/span><\/p>\n

        20. Disclaimer<\/span><\/p>\n

        21. About DelveInsight<\/span><\/p>\n

        Related Reports:<\/strong><\/p>\n

        Leber’s Hereditary Optic Neuropathy- Pipeline Insights, 2021<\/span><\/strong><\/p>\n

        “<\/span>Leber’s Hereditary Optic Neuropathy- Pipeline Insight, 2021<\/span>” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Leber’s Hereditary Optic Neuropathy market. A detailed picture of Leber’s Hereditary Optic Neuropathy pipeline landscape is provided, which includes the disease overview and Leber’s Hereditary Optic Neuropathy treatment guidelines.<\/span><\/p>\n

        Leber’s Hereditary Optic Neuropathy (LHON) -Epidemiology Forecast to 2030<\/span><\/strong><\/p>\n

        DelveInsight’s <\/span>‘Leber’s Hereditary Optic Neuropathy (LHON) – Epidemiology Forecast to 2030’ <\/span>report delivers an in-depth understanding of the disease, historical and forecasted Leber’s Hereditary Optic Neuropathy( LHON);l epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/span><\/p>\n

        Media Contact<\/span>
        Company Name:<\/strong>         DelveInsight Business Research LLP<\/a>
        Contact Person:<\/strong> Kritika Rehani
        Email:<\/strong>         Send Email<\/a>
        Phone:<\/strong> 9193216187
        Address:<\/strong>304 S. Jones Blvd #2432
        City:<\/strong> Las Vegas
        State:<\/strong> Nevada
        Country:<\/strong> United States
        Website:<\/strong>         https:\/\/www.delveinsight.com\/<\/a><\/p>\n

        <\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

        DelveInsight Business Research LLP DelveInsight\u2019s \u201cLeber\u2019s Hereditary Optic Neuropathy \u2013 Market Insights, Epidemiology, and Market Forecast-2030\u201d report delivers an in-depth understanding of the Leber\u2019s Hereditary Optic Neuropathy , historical and forecasted epidemiology as well as the Leber\u2019s Hereditary Optic Neuropathy … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-544893","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/544893","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=544893"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/544893\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=544893"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=544893"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=544893"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}